Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 309Neoplasms 269Prostatic Neoplasms 189Precursor Cell Lymphoblastic Leukemia-Lymphoma 186Lymphoma 184Leukemia, Lymphocytic, Chronic, B-Cell 161Melanoma 158Leukemia 154Lymphoma, Non-Hodgkin 149Leukemia, Myeloid, Acute 149Brain Neoplasms 143Carcinoma, Non-Small-Cell Lung 141Lymphoma, Large B-Cell, Diffuse 128Colonic Neoplasms 128Lymphoma, Follicular 123Burkitt Lymphoma 119Ovarian Neoplasms 117Lung Neoplasms 116Glioblastoma 116Lymphoma, Mantle-Cell 114Unspecified Adult Solid Tumor, Protocol Specific 107Rectal Neoplasms 103Sarcoma 102Multiple Myeloma 102Gliosarcoma 102Hodgkin Disease 97Carcinoma, Renal Cell 97Lymphoma, B-Cell, Marginal Zone 96Astrocytoma 95Carcinoma, Ovarian Epithelial 93

Interventions

Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NIH × Recurrent Uterine Corpus Carcinoma × Clear all
NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡